Health Canada approves Rybelsus to treat type 2 diabetes.- Novo Nordisk

Health Canada has approved Rybelsus (semaglutide tablets) from Novo Nordisk as a treatment option to improve glycemic control in adults with type 2 diabetes mellitus, along with diet and exercise. Rybelsus is the first and only glucagon-like peptide-1 (GLP-1) analogue available in a tablet and is indicated as a monotherapy when metformin is considered inappropriate due to intolerance or contraindications.

Rybelsus can be used in combination with other medicinal products for the treatment of type 2 diabetes in adults. Rybelsus will be available in pharmacies across Canada beginning April 27, 2020.